Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879769 | 0.81 | TRPV1 (0.51) | TRPV1POLBL3MBTL1RAB9AKMT2A | |
| SCHEMBL3128204 | 0.81 | LMNA (0.52) | CETPLMNAPOLBPDK1PDK2 | |
| SCHEMBL4870194 | 0.81 | TRPV1 (0.49) | TRPV1LMNAPOLBRAB9ANPC1 | |
| SCHEMBL10072798 | 0.77 | CETP (0.54) | CETPLMNAPOLBL3MBTL1RAB9A | |
| SCHEMBL397003 | 0.77 | PDK1 (0.67) | CETPLMNAPOLBPDK1PDK2 | |
| SCHEMBL9833634 | 0.77 | LMNA (0.55) | CETPLMNAPOLBPDK1PDK2 | |
| SCHEMBL9835326 | 0.76 | LMNA (0.54) | CETPLMNAPOLBPDK1PDK2 | |
| SCHEMBL14003063 | 0.75 | TRPV1 (0.43) | TRPV1POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL14667350 | 0.74 | CETP (0.51) | CETPLMNAPOLBPDK1PDK2 | |
| SCHEMBL2209111 | 0.74 | ALDH1A1 (0.49) | CETPLMNAPOLBPDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-9745323-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-20160303089-A1 | COMPOUND PERTAINING TO NEUROPOIESIS AND DRUG COMPOSITION | KYOTO UNIVERSITY (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | VHL, TP53, COMT | TRPV1 2062/4885CETP 1513/4885LMNA 3876/4885 |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | VHL, TP53, COMT | TRPV1 2062/4885CETP 1513/4885LMNA 3876/4885 |
| US-20160303089-A1 | COMPOUND PERTAINING TO NEUROPOIESIS AND DRUG COMPOSITION | BDNF, DCX, NTRK2 | TRPV1 1027/4885CETP 4080/4885LMNA 4473/4885 |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | VHL, TP53, COMT | TRPV1 2062/4885CETP 1513/4885LMNA 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.